TARDBP and amyotrophic lateral sclerosis: The antibody concentrations in CSF have been reported in the range of 0.1% as compared to levels in the plasma.37 In addition, the BBB integrity in ALS could further enhance the distribution of drugs in the CNS of ALS patients.38,39 As this therapeutic antibody targeting TDP-43 may be the first in ALS clinical trial, this research has been focused on having assays that help determine the PK/PD relationships in patients to help define the safe dose needed for larger Phase 2 and 3 trials.